Want to see GOSS full AI Analyst Report?
GOSS Stock Chart & Stats
$0.14
>-$0.01(-4.56%)
At close: 4:00 PM EDT
$0.14
>-$0.01(-4.56%)
Day’s Range― - ―
52-Week Range$0.11 - $3.87
Previous CloseN/A
Volume10.93M
Average Volume (3M)17.32M
Market Cap
$76.99M
Enterprise Value$37.16
Total Cash (Recent Filing)$57.03M
Total Debt (Recent Filing)$39.10M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Nov 05, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding488,846,700
10 Day Avg. Volume21,877,037
30 Day Avg. Volume17,317,995
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-5.77
Price to Sales (P/S)14.62
P/FCF Ratio-4.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.07Price Target Upside664.29% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-0.27
Revenue Forecast (FY)$36.86M
Bulls Say, Bears Say
Bulls Say
Seralutinib Shows Multidimensional Clinical And Mechanistic SupportThe clinical benefit, supportive secondary endpoints and imaging evidence provide a broader efficacy thesis than a single measure. These signals may strengthen differentiation and regulatory discussions, although the primary endpoint’s statistical miss remains a constraint.
Defined FDA Pathway Supports Potential Seralutinib SubmissionA scheduled regulatory interaction and defined submission timeline give the lead program a concrete development path. If FDA feedback remains supportive, this can convert late-stage clinical assets into a potential commercial opportunity.
Milestone-linked Financing Could Extend Development RunwayCommitted and milestone-based financing can fund regulatory execution and late-stage development while reducing immediate dependence on repeated capital raises. Investor participation also provides external support for the seralutinib strategy.
Bears Say
Heavy Cash Burn And Persistent UnprofitabilityLarge operating losses and sustained cash outflows indicate that the business is not yet self-funding. Continued development and commercialization spending will require financing or major revenue growth, increasing execution and dilution risk.
Negative Equity And Shrinking Asset CushionNegative equity and a materially smaller asset base reduce financial flexibility and the cushion available to absorb further losses. This weak balance sheet leaves the company more exposed to financing conditions and operational setbacks.
Primary Endpoint Miss Increases Regulatory UncertaintyMissing the study’s prespecified statistical threshold weakens the evidentiary foundation for approval and may require FDA reliance on secondary or confirmatory data. This creates lasting uncertainty around filing acceptance, review and approval timing.
Gossamer Bio News
GOSS FAQ
What was Gossamer Bio’s price range in the past 12 months?
Gossamer Bio lowest stock price was $0.11 and its highest was $3.87 in the past 12 months.
What is Gossamer Bio’s market cap?
Gossamer Bio’s market cap is $76.99M.
When is Gossamer Bio’s upcoming earnings report date?
Gossamer Bio’s upcoming earnings report date is Nov 05, 2026 which is in 74 days.
How were Gossamer Bio’s earnings last quarter?
Gossamer Bio released its earnings results on Aug 13, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.123 by $0.043.
Is Gossamer Bio overvalued?
According to Wall Street analysts Gossamer Bio’s price is currently Undervalued.
Does Gossamer Bio pay dividends?
Gossamer Bio does not currently pay dividends.
What is Gossamer Bio’s EPS estimate?
Gossamer Bio’s EPS estimate is -0.05.
How many shares outstanding does Gossamer Bio have?
Gossamer Bio has 488,846,700 shares outstanding.
What happened to Gossamer Bio’s price movement after its last earnings report?
Gossamer Bio reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.123. Following the earnings report the stock price went down -9.412%.
Which hedge fund is a major shareholder of Gossamer Bio?
Currently, no hedge funds are holding shares in GOSS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gossamer Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.07 (664.29% Upside)
$1.07 (664.29% Upside)
Blogger Sentiment
Neutral
GOSS Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-92.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-68.09%
Trailing 12-Months
Company Description
Gossamer Bio
Gossamer Bio, Inc. (GOSS) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing medicines for patients with immunologic and inflammatory diseases and, historically, select oncology programs. The company’s activities center on advancing a pipeline of drug candidates through clinical development, with a strategic focus on immunology and inflammation assets.
GOSS Company Deck
GOSS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed but constructive picture: clinically meaningful efficacy signals (including a traditional statistical threshold for 6MWD), supportive mechanistic CT FRI data across multiple lung compartments with clinical correlations, and decisive capital actions (debt reduction plan and cost containment) to preserve runway and focus on an NDA path. Counterbalancing these positives were key execution risks — the primary endpoint did not meet the prespecified alpha, a substantial workforce reduction was implemented, cash runway is short ($99M to Q1 2027), and the debt exchange depends on high noteholder participation and involves tradeoffs. Overall, the tone is cautious and pragmatic, emphasizing strengthened conviction in the program but acknowledging material near-term financial and regulatory risks.View all GOSS earnings summariesGOSS Stock 12 Month Forecast
Average Price Target
$1.07
▲(664.29% Upside)
Technical Analysis
Aldeyra Therapeutics
―
Cue Biopharma
―
Tiziana Life Sciences
―
Alector
―
Connect Biopharma Holdings
―
Ownership Overview
1.86% Insiders
3.62% Mutual Funds
38.41% Other Institutional Investors
52.09% Public Companies and
Individual Investors